|
Caprion Pharmaceuticals announced a research collaboration with Berlex |
|
|
|
25 Jan 2006 |
Montreal. CA |Jan. 24, 2006 | Caprion Pharmaceuticals Inc. today announced a research collaboration with Berlex Inc., a US affiliate of Schering AG Germany (NYSE: SHR, FSE: SCH). The collaboration will use Caprion’s CellCarta® proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development.
"Caprion is looking forward to working with Berlex on their pre-clinical therapeutic candidates," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion. "We believe Caprion’s capabilities in the discovery of protein biomarkers will significantly impact our partner’s development efforts."
Caprion’s proprietary proteomics platform comprehensively profiles the expression and identity of proteins detected in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.
###
About Caprion Pharmaceuticals Inc.
Caprion is a drug discovery and development company applying its proprietary proteomics technologies to develop innovative pharmaceutical products, initially in oncology and infectious disease. The Company's most advanced program will enter Phase II clinical trials in the US for Shiga-toxin producing E. coli infection (STEC) in the third quarter of 2006. Caprion’s proteomics discovery platform – CellCarta® - has become a leading means for profiling proteins in blood and solid tumors. Caprion’s strategy is to leverage platform discovery and development collaborations in two key areas – oncology and plasma profiling – to fund and further build its own pipeline of clinical programs. In addition to its leading program in STEC, Caprion has signed major research alliances in Colon, Prostate and Lung Cancer with Biogen Idec, AstraZeneca, ICOS Corporation, Abbott Laboratories and ImClone Systems, as well as numerous alliances for plasma profiling and novel biomarker discovery with leading pharmaceutical companies. For more on Caprion, please visit www.caprion.com.
SOURCE: Caprion Pharmaceuticals
|
